The global sales of lacrimal devices are estimated to be worth USD 32.1 million in 2025 and anticipated to reach a value of USD 57.0 million by 2035. Sales are projected to rise at a CAGR of 5.9% over the forecast period between 2025 and 2035. The revenue generated by lacrimal devices in 2024 was USD 30.4 million.
Dacryocystorhinostomy, DCR, is a procedure which is one time and can be performed as an out-patient procedure, with a great success rate. In this course of the procedure, a lacrimal duct stent tube is placed to prevent the closure of the duct. The success rate of DCR, under stenting, in terms of reducing epiphora, is more than 90%.
Lacrimal duct stent tubes are placed within the lacrimal duct for six to eight weeks, or even longer, depending on the severity of the case. DCR further improves the compliance and motivation of doctors and patients. If the prescribed care is considered up until the time of lacrimal duct stent tube removal, any chance of complications involved with the stent is minimal.
Global Lacrimal Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 30.4 million |
| Estimated Size, 2025 | USD 32.1 million |
| Projected Size, 2035 | USD 57.0 million |
| Value-based CAGR (2025 to 2035) | 5.9% |
Developing countries are experiencing high birth rate as compared to developed countries, representing significant revenue generation potential. Manufacturers in the lacrimal duct stent tube market are partnering with various countries/regional level distributors in order to enhance their product availability. For example, FCI Ophthalmics Inc. collaborated with Devine Medihealth of India to avail products in the high revenue potential market.
Increasing product availability helps in increasing awareness about the nasolacrimal duct obstruction condition and available treatment options, which is expected to result in enhanced product adoption in developing region. Product awareness among ophthalmologists is expected to play a significant role in market growth over the forecast period as compared to awareness among general population.
If nasolacrimal duct obstruction are not treated effectively, it can cause inflammation/infection of the tear duct. Among adults, the condition often affects work life conditions. Patients are also worried about facial scar, and hence minimal invasive nature of transnasal endoscopic DCR procedure often let people opt for this treatment.
Endoscopic DCR procedure and lacrimal duct stenting treats patients more effectively without leaving any scars, which is attracting more patients to go for the treatment. The minimal invasive nature of DCR procedure followed by stenting also positively impacts the nasolacrimal duct obstruction treatment in newborns. minimal invasive nature of lacrimal duct stenting and dcr procedure driving the market.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The below table presents the expected CAGR for the global sales of lacrimal devices over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2035, the business is predicted to surge at a CAGR of 7.0%, followed by a slightly lower growth rate of 6.6% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.0% (2024 to 2034) |
| H2 | 6.6% (2024 to 2034) |
| H1 | 5.9% (2025 to 2035) |
| H2 | 5.5% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.9% in the first half and decrease moderately at 5.5% in the second half. In the first half (H1) the market witnessed a decrease of 110.0 BPS while in the second half (H2), the market witnessed a increase of 110.0 BPS.
Advancement in Nasolacrimal Duct Obstruction Treatment Demands the use of Lacrimal Devices
With over one fifth of newborns with nasolacrimal duct obstruction disorder, the treatment approach is often decided based on how severe it is. Earlier, ophthalmologists used to consider conservative approach with anti-inflammatory and antibiotics for the treatment, which showed limited effectivity. With dacryocystorhinostomy (DCR) procedure, management of the lacrimal duct obstruction became easier with high success rate.
Usage of lacrimal duct stent tube for the correction of lacrimal duct or in building completely new lacrimal duct, resulted in superior efficacy with greater success rate as compared to conservative approach.
Lacrimal stent provides more safer and effective approach for the management of lacrimal duct obstruction. Various manufacturers are introducing new lacrimal duct stent tubes made of different material and length and this results in more personalized approach in treating nasolacrimal duct obstruction.
In this decade, manufacturers in the lacrimal duct stent tube market focused on correcting their product to enhance patient compliance, resulting in enhanced ophthalmologist's preference for lacrimal duct stent tubes over other devices such as catheters.
Increasing Number of Births and Decreasing Infant Mortality Rate increased Demand in Market
Very high number of births coupled with falling infant mortality has greatly enhanced market demand for this product sector, particularly in countries like India and China, where the fertile population is on the rise. These nations significantly contribute to the world newborn population each year.
Developing regions in Asia and Africa have the most number of population additions, due to improved access to healthcare, increased investment in neonatal care, and governmental initiatives. This demographic expansion bolsters demand for infant products and services, thereby giving these regions considerable significance in market expansion.
Advancements in medicine and industrial revolution are immediate factors assisting to the increasing number of newborn population each year. Developed countries are also initiating various programs to keep up with the existing fertile population ratio to that of overall population.
Advancements in the field of medicine, initiatives by World Health Organization, UNICEF, etc. to tackle the infant mortality have also assisted increased newborn survival with reduced infant mortality. In 1990, there were around 5 million newborns whereas in 2023, it is halved due to various initiatives by global. With increasing number of newborns in year-on-year basis, it is expected to assist the growth of the lacrimal duct stent tube market.
Greater Focus on Product Awareness will Create Opportunities in the Market
Increasing awareness about the availability and subsequent adoption of lacrimal duct stent tube devices are expected to generate significant revenue. Awareness about the availability and efficacy among healthcare professionals is expected to play a major role in increased adoption of devices for nasolacrimal duct obstruction management.
There are various variants of lacrimal duct stent tube available in the market, which represents vast revenue generation opportunity.
The Lacrimal Devices sector is on the verge of growth, a growth engendered by rising awareness about the devices that feel their way into the lacrimal duct stent tube group. With the ability to treat na-solacrimal duct obstructions, these devices are becoming very popular as they can aid in the restoration of proper tear passage and have been known to facilitate improvements in patient outcomes.
The increasing knowledge among healthcare providers of the existence and efficacy of these devices has helped them gain foothold in the market.
The availability of lacrimal duct stent tubes is numerous and offers varied commercial opportunities. Innovative technology includes device design, materials, and less invasive surgical options adopted for these products that entice the ophthalmologists and the surgeons.
The demand within the Lacrimal Devices segment is further boosted by the increasing prevalence of lacrimal system disorders, especially in aging populations, and the increase in awareness about ophthalmic health. Emerging economies in Asia-Pacific, Africa, and the Middle East are anticipated to provide very lucrative opportunities as healthcare infrastructure expands and access to advanced therapeutic deliveries continues to grow.
Complications Associated with Lacrimal Duct Stent Tube May Restrict the Market
In dacryocystorhinostomy (DCR) procedure, several complications such as corneal abrasion, canaliculitis, prolapse, etc. may occur. Lacrimal duct stent tubes may be displaced and come out via lacrimal duct towards eye or nasal cavity, resulting in uneasiness and rarely resulting in false passage creation during intubation, cheese wiring of the punctum.
Although, manufacturers in the lacrimal duct stent tube market are correcting the flaws by altering the length, the material used for manufacturing, etc., the process still has risk of complications, considering the age group in which stenting is carried out. These complications may hamper the potential growth of the market.
Despite the fact that manufacturers in the lacrimal devices space are fixing problems by changing the length, manufacturing material, and other factors, the method still poses a risk of difficulties, especially given the age range for which stenting is performed. These problems may limit the market's future expansion.
The majority of lacrimal devices manufacturers are based in developed regions such as North America and Europe. Latin America, East and South Asia, and other developing nations frequently rely on western manufacturers. As a result, product availability is constrained in a number of high-revenue-potential locations, stifling market expansion.
Manufacturers who do not have a regional production plant rely on multiple regional or country-level distributors to get their goods into the market. It frequently leads to increased product costs and limited availability. Despite the fact that manufacturers are eager to expand their regional product footprints, their efforts are still limited.
The evaluation of lacrimal devices safety is an important part of the development process, which can be challenging. The market for lacrimal devices is hampered by the problems described above.
The global sales of lacrimal devices recorded a CAGR of 5.6% during the historical period between 2020 and 2024. The growth of lacrimal devices sector to remain positive and reached a value of USD 32.1 million by 2025 from USD 24.3 million in 2020.
Multiple approaches are taken to treat nasolacrimal duct obstruction, where the lesser number of treatments fails to give such an effective healing potential, certain DCRs have to expose risks such as scarring, damage to the adjoining structures, infection, and prolonged healing period.
The untreated lacrimal devices present minimally invasive treatment solutions to every challenge faced, with greater accuracy and reduced complication risks, shorter healing periods, and improved patient outcomes.
Nasolacrimal duct obstruction has become one of the most commonly diagnosed conditions involving the lacrimal system. While there has been spontaneous resolution of many cases in infants, some will warrant medical intervention, especially if associated with underlying conditions or syndromes. The increased demand for effective techniques has left large new clinical windows for innovative devices.
Among these are the bicanalicular devices, which have become increasingly accepted for their usability and compatibility with implantation materials. This combination has promoted higher patient compliance and better clinical outcomes, forming a classic supportive approach for the management of nasolacrimal duct disorders.
With climbing priority into focus for patient-friendly alternatives in minimally invasive techniques, the devices' position will remain advantageous and subsequently develop and expand the market.
Companies in Tier 1 are those dominant in the market with significant shares, driven by their investment in R&D, strategic partnerships, and standpoints in clinical trials for the innovativeness of lacrimal device solutions.
Companies like FCI Ophthalmics, Kaneka Corporation, Gunther Weiss Scientific Glass, and Bess Medizintechnik dominate the lacrimal device market by offering advanced, high-quality medical devices for treatment of a variety of ailments of the lacrimal system. They are noted for being truly global companies committed to innovations that maintain their leadership.
Tier 2 companies are dominant in a regional market mainly through inexpensive manufacturing processes in collaboration with their research institutions. These companies cannot compete with Tier 1 on a global level, but are rather suppliers that provide unique contributions toward very specific regional markets, with affordable specialized lacrimal devices aimed at meeting local needs.
Tier 3 companies cater to specialty or niche markets through providing niche lacrimal devices for certain applications. Although their share is small, they add a limited contribution to the market, addressing some special needs in lacrimal care and injecting diversity and innovation into the overall landscape of the market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the industry analysis for the lacrimal devices across different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and MEA, is provided.
The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In Asia Pacific, India is projected to witness a CAGR of 6.4% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 5.4% |
| Germany | 5.9% |
| China | 5.6% |
| France | 5.8% |
| India | 6.4% |
| Spain | 5.3% |
| South Korea | 6.2% |
The sales in United States lacrimal devices is expected to grow at a CAGR of 5.4% between 2025 and 2035. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
The North America market will reportedly be accounting for a near one-third share during the research phase because of its well-established medical industry and high healthcare spending. The upsurge in demand for lacrimal devices has been influenced by growing advances in ophthalmology facilities, with concomitant surges in the incidence of lacrimal diseases.
The positive trend is being complemented by increased per capita health care spending and supportive government initiatives that promote integrated health care systems, leading to enhanced access for consumers to advanced treatments and driving adoption rates.
Coupled with an increasing prevalence of retinal disorders, these present lucrative opportunities for market participants since these pathologies are largely treated with adjunctive ophthalmic interventions. Overall, this is expected to enable the USAto lead toward global lacrimal device marketplace development.
China’s lacrimal devices market is poised to exhibit a CAGR of 7.6% between 2025 and 2035. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
China's lacrimal devices market is expected to witness growth on account of several factors. Firstly, the booming healthcare infrastructure in the country is improving the access to advanced therapies, including lacrimal devices. Secondly, the rising awareness among patients regarding ophthalmic health and improved diagnostics capabilities are increasingly convincing patients to seek treatment for disorders affecting the lacrimal passages.
Additionally, the rising prevalence of disorders associated with age, dry eye syndrome, like congenital lacrimal duct obstructions, coupled with the expansion towards minimally invasive treatment options, is directly influencing the growing demand for lacrimal devices. These factors, among several others, will be working to provide significant growth in the market.
The sales of lacrimal devices in Germany is poised to exhibit a CAGR of 8.0% between 2025 and 2035. Currently, it holds the highest share in the Western Europe market, and the trend is expected to continue during the forecast period.
Germany's strength is founded on the regulatory framework for surgical devices that is well-defined and the growing effort of the population to understand treatments for lacrimal duct obstruction and related health problems. This set of conditions has favoured the penetration of advanced lacrimal devices in the country.
For meeting the demands of the patients in an effective way, companies in the industry have nurtured a very healthy relationship with the hospitals and the ophthalmic clinics along with direct channels for hospitals and clinics for access to these products. Additionally, companies are involved in strategic partnerships and acquiring major clinics and hospitals within Germany.
These initiatives are aimed at improving their operations, extending market reach, and catering to the ever-increasing demand for innovation in treatments for lacrimal systems in the region.
The section contains information about the leading segments in the industry. By product, the bicanalicular lacrimal duct stent tube segment holds the highest market share of 74.6% in 2025.
| By Product | Bicanalicular Lacrimal Duct Stent |
|---|---|
| Value Share (2025) | 74.6% |
The bicanalicular lacrimal duct stent accounted 74.6% of the market in 2025. Two probes with an intermediate stent are used in bicanalicular lacrimal tubes. Bicanalicular lacrimal intubation is an effective treatment for children with nasolacrimal duct obstruction; highest rate of success has been attributed to younger patients.
Ease of handling, heightened patient compliance, and material compatibility of the bicanalicular duct stent without eliciting adverse reactions are the major driving forces for the growth of this segment in the coming years.
These advantages make bicanalicular devices the preferred option for nasolacrimal duct obstruction treatment, particularly in pediatric cases. As this factor has ruled the tackling of nasolacrimal duct obstruction by pediatricians, it has contributed to the burgeoning growth and increased market uptake.
| By End User | Hospitals |
|---|---|
| Value Share (2025) | 48.8% |
Hospitals holds leading revenue share of over 48.8% of the total global lacrimal devices sales and are expected to continue to do so for the whole duration of the forecasts. Due to their ability to provide maximum device availability to patients who need treatment, hospitals are likely to remain the most profitable segment.
These healthcare facilities provide complete care systems that provide lacrimal device surgery, thereby encompassing the whole continuum of outpatient services and even being the main point of access for an individual needing treatment. The hospitals enjoy this dominance due to unabated accessibility, provision of intensive treatments, and a broad infrastructure well in place.
Leading lacrimal device manufacturers are focusing on geographic growth in order to increase revenue and expand their sales presence in emerging markets by acquiring local market players.
Recent Industry Developments in Lacrimal Devices Industry
In terms of product, the industry is divided into- monocanalicular lacrimal duct stent tube and bicanalicular lacrimal duct stent tube
In terms of end user, the industry is segregated into hospitals, ophthalmic clinics and ambulatory surgical centers
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global revenue of lacrimal devices is projected to witness CAGR of 5.9% between 2025 and 2035.
The global lacrimal devices industry stood at USD 30.37 million in 2024.
The global sales of lacrimal devices is anticipated to reach USD 57.0 million by 2035 end.
India is set to record the highest CAGR of 5.6% in the assessment period.
The key players operating in the global lacrimal devices sector include FCI Ophthalmics, Kaneka Corporation (Kaneka Pharma America LLC), Gunther Weiss Scientific Glass and Bess Medizintechnik GmBH
| Estimated Size, 2025 | USD 8,125.2 million |
|---|---|
| Projected Size, 2035 | USD 11,890.2 million |
| CAGR (2025 to 2035) | 3.9% |
| Estimated Size, 2025 | USD 32.1 million |
|---|---|
| Projected Size, 2035 | USD 57.0 million |
| Value-based CAGR (2025 to 2035) | 5.9% |
| Market Size (2024E) | USD 17,271.8 million |
|---|---|
| Market Value (2034F) | USD 25,876.4 million |
| Value-based CAGR (2024 to 2034) | 4.7% |
| Market Estimated Value (2023) | USD 1.37 billion |
|---|---|
| Market Estimated Value (2033) | USD 2.48 billion |
| Market Value CAGR (2023 to 2033) | 6.1% |
Explore Therapeutic Device Insights
View Reports
Lacrimal Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
